Jefferies analyst Chris Howerton reiterated a Buy rating and $60.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD), citing pimavanserin's versatility ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE